Jul 22, 2018 | News
T3D Therapeutics, Inc. today announced that final Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in a session at the 2018 Alzheimer’s Association International Conference (AAIC) entitled ‘Novel Therapeutic Approaches for...
Mar 12, 2018 | News
T3D Therapeutics, Inc. today announced that FDG-PET neuroimaging data from a Phase 2a trial with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in an oral and poster presentation entitled ‘A Neurometabolic Approach to Treating Alzheimer’s...
Mar 28, 2017 | News
RESEARCH TRIANGLE PARK, NC (PRWEB) MARCH 28, 2017 – T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen Welsh-Bohmer...
Dec 1, 2016 | News
Research Triangle Park, NC (PRWEB) November 30, 2016 — T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that CEO, John Didsbury, will...
Aug 3, 2016 | News
T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that preliminary Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease...
